Tectonic Therapeutic, Inc. (TECX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$30.75+2.77%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TECX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
TECX — earnings miss
Dated 2026-05-07
Results of Operations and Financial Condition. On May 7, 2026, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with
Why it matters: Changes in expenses will show if Tectonic is controlling costs amid ongoing losses. This impacts financial health.
Worry ifOperating expenses are lower than in Q2 2026.
Less concerning ifOperating expenses are higher than in Q2 2026.
Why it matters: Results will indicate TX45's potential as a treatment for PH-HFpEF. This could impact the company's future.
Supportive ifTopline results from the TX45 APEX Phase 2 trial expected early Q1 2027.
Worry ifResults show no big change in pulmonary vascular resistance. This may lead to trial changes.
Why it matters: Topline results will show if TX2100 is safe and effective for HHT. This is key for future trials.
Supportive ifTopline results for TX2100 Phase 1a trial reported by the end of Q3 2026.
Worry ifResults show safety or tolerability issues. This may delay trials.
Why it matters: Progress on these trials is crucial for future growth and investor confidence.
Supportive ifManagement shares good trial results or milestones for TX45 and TX2100.
Worry ifManagement reports delays or negative results from TX45 and TX2100 trials.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$274 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $650 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,639 loss on $10,000 · 26.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A timeline for TX45's Phase 2 readout shows progress in clinical development.
Supportive ifManagement confirms the Phase 2 readout for TX45 is on track for the projected timeline.
Worry ifManagement delays the Phase 2 readout timeline for TX45.
Why it matters: Cash position impacts the company's ability to fund ongoing trials. A decline could raise concerns.
Worry ifCash and cash equivalents remain above $227 million at the end of Q3 2026.
Less concerning ifCash and cash equivalents drop below $220 million.